Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
äŒæ¥ã³ãŒãMIST
äŒç€ŸåMilestone Pharmaceuticals Inc
äžå Žæ¥May 09, 2019
æé«çµå¶è²¬ä»»è
ãCEOãOliveto (Joseph)
åŸæ¥å¡æ°33
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 09
æ¬ç€Ÿæåšå°420-1111 boul. Dr.-Frederik-Philips
éœåžMONTREAL
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœCanada
éµäŸ¿çªå·H4M 2X6
é»è©±çªå·15143360444
ãŠã§ããµã€ãhttps://www.milestonepharma.com
äŒæ¥ã³ãŒãMIST
äžå Žæ¥May 09, 2019
æé«çµå¶è²¬ä»»è
ãCEOãOliveto (Joseph)